Home Patent Forecast® Sectors Log In   Sign Up   Support   Contact  
Why Patent Forecast® What's Included Patent Forecast® Sectors Free Trial Pricing News Feed Subscribe Menu

Patent 10765643
Gw Pharmaceuticals, Plc

Use Of Cannabidiol In The Treatment Of Epilepsy

The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome. In one embodiment the seizures associated with Aicardi Syndrome are convulsive seizures; focal seizures with impairment or infantile spasm. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).

Slightly Less than Average Length Specification


1 Independent Claims

  • Claim 1. A method of treating seizures in a subject having Aicardi Syndrome, comprising administering to the subject in need thereof cannabidiol (CBD), wherein the CBD ispresent in a composition at a concentration ranging from about 25 mg/ml to about 100 mg/ml, ethanol is present in the composition at a concentration of about 79 mg/ml, sucralose at a concentration of about 0.5 mg/ml, strawberry flavoring is present inthe composition at a concentration of about 0.2 mg/ml and sesame is present in the composition at an amount up to about 1.0 ml.
  • Claim 9. A method of treating seizures in a subject having Aicardi Syndrome, comprising administering to the subject in need thereof cannabidiol (CBD) at a dose ranging from 5 mg/kg/day to 25 mg/kg/day, wherein the CBD is present in a composition ata concentration ranging from about 25 mg/ml to about 100 mg/ml, ethanol is present in the composition at a concentration of about 79 mg/ml, sucralose at a concentration of about 0.5 mg/ml, strawberry flavoring is present in the composition at aconcentration of about 0.2 mg/ml and sesame is present in the composition at an amount up to about 1.0 ml.